New Stock Tracker: confidence in molecular Dx sector boosts Ipsogen
This article was originally published in Clinica
Executive Summary
With the credit crisis in full swing, medical devices firms have found it difficult to stimulate enough investor support to be able to go public, let alone maintain a healthy share price. One firm that has bucked the trend is French molecular diagnostics firm Ipsogen (ALIPS).